Detalles de la búsqueda
1.
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
Am Heart J
; 208: 81-90, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30580130
2.
Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.
Clin Transl Sci
; 15(10): 2331-2341, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35933730
3.
Dihydronepetalactones deter feeding activity by mosquitoes, stable flies, and deer ticks.
J Med Entomol
; 46(4): 832-40, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19645285
4.
CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.
J Am Heart Assoc
; 13(9): e033541, 2024 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700008
5.
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
Clin Pharmacol Drug Dev
; 8(5): 628-636, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30240132
Resultados
1 -
5
de 5
1
Próxima >
>>